Cancer Epigenetics & Oncology
Epigenetic modifications of the Cancer cell genome, which does not bring a change in the nucleotide sequence, is called Cancer Epigenetics.
Cancer was the first human disease to be linked to epigenetics. DNA hypomethylation can activate oncogenes and initiate chromosome instability, whereas DNA hypermethylationinitiates silencing of tumor suppressor genes. An accumulation of epigenetic & genetic errors can transform a normal cell into an invasive or metastatic tumor cell. DNA methylation patterns may cause abnormal expression of cancer-associated genes. Global histone modification patterns are also found to correlate with cancers such as breast, prostate, and pancreatic cancer.
Epigenetic modification are as important as genetic mutations in a cell's transformation to cancer, and their manipulation holds great promise for cancer prevention, detection, and therapy.
During the cell transformation to a cancerous cell, Epigenetic modifications are also crucial like genetic mutations. Their modification brings a great promising approach for prevention, detection, and therapy of Cancer.
- Novel epigenetics targets in cancer
- Histone variants and histone modifications
- Cancer stem cells
- Epigenetic tools and technologies
- Epigenetic & Genetic aspects of breast cancer progression
- Breast cancer risk and prevention
Related Conference of Cancer Epigenetics & Oncology
18th International Conference on Human Genomics and Genomic Medicine
21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Cancer Epigenetics & Oncology Conference Speakers
Recommended Sessions
- Biochemical approaches of Epigenetics
- Bioinformatics/ Computational Analysis of Epigenetics
- Brain disorders & Epigenetics
- Cancer Epigenetics & Oncology
- Chromatin & its Dynamics
- Cyto-epigenetic approaches
- Environmental Epigenetic Factor
- Epigenetics
- Epigenetics in Biotechnology & Developmental Biology
- Epigenetics in Cardiovascular Disease
- Epigenetics in Clinical Practice
- Epigenetics in Nervous System
- Epigenetics in Pharmacology & Drug Discovery
- Epigenetics in reproductive health
- Epigenetics Market Products & Instrumentation
- Genetics & Epigenetic inheritance
- Genomics and Epigenetics Division
- Immunology in the epigenetic era
- Medical Epigenetics
- Microbial Epigenetics
- Need of Epigenetic Biomarkers
- Plant Epigenetics
- Toxicoepigenetics
Related Journals
Are you interested in
- Achieving efficient delivery and editing - CRISPR 2025 (Italy)
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (France)
- Bioinformatics - HUMAN GENOME 2025 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (France)
- Cancer and stem cells - CRISPR 2025 (Italy)
- Cancer Genomics - HUMAN GENOME 2025 (France)
- Cancer Stem Cells and Oncology - Stemgen 2026 (France)
- Cardiovascular Regeneration - Stemgen 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (France)
- Cognitive Computing - HUMAN GENOME 2025 (France)
- Computational Biology - HUMAN GENOME 2025 (France)
- CRISPR technologies and society - CRISPR 2025 (Italy)
- CRISPR technologies beyond genome editing and gene regulation - CRISPR 2025 (Italy)
- Drug Detection & Development in Bioinformatics - HUMAN GENOME 2025 (France)
- Emergency Medicine - HUMAN GENOME 2025 (France)
- Epigenetics Biomarkers - HUMAN GENOME 2025 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (France)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (France)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (France)
- Genetically Modified Organisms - HUMAN GENOME 2025 (France)
- Genome editing and gene regulation in human health - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial bacterial biotechnology - CRISPR 2025 (Italy)
- Genome editing and gene regulation in industrial eukaryotic biotechnology - CRISPR 2025 (Italy)
- Genome Editing Methods and Novel Tools - CRISPR 2025 (Italy)
- Genome Mapping - HUMAN GENOME 2025 (France)
- Genomic Approach to Drug Discovery - HUMAN GENOME 2025 (France)
- Genomic Information in Medicine - HUMAN GENOME 2025 (France)
- Genomic Vaccination - HUMAN GENOME 2025 (France)
- Genomics - HUMAN GENOME 2025 (France)
- Horizons of CRISPR biology - CRISPR 2025 (Italy)
- Human Gene Therapy - HUMAN GENOME 2025 (France)
- Human Genetics - HUMAN GENOME 2025 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (France)
- Infectious Diseases - HUMAN GENOME 2025 (France)
- Medicine Genomics - HUMAN GENOME 2025 (France)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (France)
- Personalized Medicine - HUMAN GENOME 2025 (France)
- Pharma Genomics & Pharma Informatics - HUMAN GENOME 2025 (France)
- Plant and Animal Biotechnology - CRISPR 2025 (Italy)
- Preimplantation Genetic Diagnosis - HUMAN GENOME 2025 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (France)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (France)
- Structural Biology and Bioinformatics - CRISPR 2025 (Italy)
- Therapeutic Genome Editing - CRISPR 2025 (Italy)

